False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T‐VEC)

Talimogene laherparepvec (T‐VEC) is a genetically modified herpes simplex virus‐1‐based oncolytic immunotherapy and has been approved for the local treatment of unresectable (stage IIIB/C and IVM1a) cutaneous melanoma. During T‐VEC treatment, tumor response is often evaluated using [18F]2‐fluoro‐2‐d...

Descripción completa

Detalles Bibliográficos
Autores principales: Mulder, Evalyn E. A. P., Stahlie, Emma H. A., Verver, Daniëlle, Lemstra, Clara, Been, Lukas B., Mooyaart, Antien L., Brabander, Tessa, Vegt, Erik, Verburg, Frederik A., van der Veldt, Astrid A. M., Verhoef, Cornelis, van Akkooi, Alexander C. J., Grünhagen, Dirk J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Melanoma, Sarcoma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596632/
https://www.ncbi.nlm.nih.gov/pubmed/34235758
http://dx.doi.org/10.1002/jso.26607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596632/
https://www.ncbi.nlm.nih.gov/pubmed/34235758
http://dx.doi.org/10.1002/jso.26607

Ejemplares similares